PUMAi

PUMAi (10 mg/kg; i.p.; 2 hours before each of 3 CPT-11 doses, plus 1 dose 20 hours after final CPT-11 dose) increases survival to 70% in mice with CPT-11-induced lethal gastrointestinal injury^[1].
PUMAi (10 mg/kg; i.p.; 2 hours before CPT-11) reduces LGR5⁺ intestinal stem cell apoptosis, niche cell expansion, and DNA damage in mice treated with CPT-11^[1].
PUMAi (10 mg/kg; i.p.; 2 hours before and 20 hours after each of 6 CPT-11 doses) prevents LGR5⁺ intestinal stem cell exhaustion and preserves niche integrity in mice treated with repeated doses of CPT-11^[1].
PUMAi (10 mg/kg; i.p.; 2 hours before and 20 hours after each of 6 CPT-11 doses) protects tumor-bearing mice from CPT-11-induced gastrointestinal injury and weight loss without compromising tumor response to chemotherapy^[1].
PUMAi (10 mg/kg; i.p.; 30 minutes before irradiation, 30 minutes after irradiation, and daily for 4 subsequent days) improves survival in mice with radiation-induced gastrointestinal injury^[1].
PUMAi (10 mg/kg; i.p.; single dose) administered 2 hours after acetaminophen overdose significantly reduces acetaminophen-induced liver necrosis and injury in mice, as evidenced by reduced serum ALT/AST levels, necrotic liver area, TUNEL-positive cells, and HMGB1 cytoplasmic translocation^[3].